The HER2 arms don't necessarily imply cetuximab combinations are succeeding. Two of the Regimens were likely designed to test FT836 with the HER2 mAb in parallel, especially given the CD16 receptor. The stronger evidence will come from expanded cohort data (if it is presented in 2H): whether activity appears beyond isolated responders, whether mono FT836 show signals, and whether paclitaxel improve outcomes versus mAb combinations alone.
Market Data 
Markets 
